Trefoil Therapeutics was founded by leaders in FGF-1 research and ophthalmic drug development with a commitment to improve the lives of patients with corneal diseases who have few current therapeutic options. Our team brings more than 100 years of collective experience in ophthalmic pharmaceutical development to our programs.

We are developing first-in class products based on our novel, engineered FGF-1, TTHX1114, to treat corneal endothelial (back of the cornea) diseases, and corneal epithelial (front of the cornea) conditions such as ulcers caused by herpes viruses. The development of these products has been supported by two rounds of venture financing, totaling $33 million; a significant Collaborative Research and Development Agreement (CRADA) with NIH’s National Center for Advancing Translational Sciences (NCATS); and a U.S. Dept. of Defense grant for proof-of-concept studies of topical TTHX1114 in the treatment of corneal injury.

Based on our progress to date, intracameral injection of TTHX1114, our lead product, has entered clinical trials in 2020 in patients with FECD, with our TTHX1114 topical product expected to begin clinical studies in 2021 for herpetic keratopathy.